

One Stop Solution
Concept to
Commercialization

ACME GROUP




Acme Formulation



Acme Generics



Immaculé



spreading health and hap





appiness across 60+ countries



legacy of trust

The Acme group began its journey in 2005 with a bold mission of becoming a leader in the contract manufacturing space and a preferred business partner for pharmaceutical companies looking for world-class capabilities and scalable operations.

Guided by the founder's vision and purpose, the Acme group, over the years, has scaled new heights in the pharmaceutical value chain and today provides fully integrated contract manufacturing and development solutions to some of the top Indian and global pharmaceutical companies.

Acme strongly believes in fast growth combined with a focus on innovation and service. Currently, the group consists of three state-of-the-art, fast-growing companies, viz. Acme Formulation, Immacule and Acme Generics.

Powering the group are 2500+ highly skilled staff working in over 500,000 sq. ft manufacturing space across Northern India, producing 15 billion tablets, 3 billion capsules, 30 million ampoules and 12 million Lyo vials. The group has also expanded into niche segments of Oral Hormones, both Sex Hormones and Levothyroxine, along with General Injectables - Liquids and Lyophilized.

In our journey over the past decade, we have been audited and approved by various international regulatory agencies, including USFDA, UK-MHRA, EU-GMP, Health Canada, TGA Australia, ANVISA, INVIMA, and WHO-Geneva. Apart from this, the Group also has approvals across major emerging countries in Asia, Africa, CIS and Latin Countries. With 10+ ANDA approved, and 30+ ANDA under filing as CDMO, we continue our journey towards building a sustainable future.

Acme looks to the future with ever higher goals and ambitions. Its unwavering focus on service and quality is strategically poised to grow even further in the years ahead.



At Acme, we offer Quality, Speed and Value by combining our technical competencies and cost-effective solutions.

Across our sites, our development teams are proficient in

- Pre-Formulation Studies: Chemical/ physical characterisation and Drug / Excipient compatibility
- Formulation Development
- Analytical Method Development and Validation
- Stability studies covering all ICH zones including container closure compatibility studies.

Commercial Manufacturing

With an investment of over USD 150 million, Acme proudly serves many of the world's leading companies. With an unwavering focus on Service and Quality, Acme is strategically positioned to serve as a preferred business partner.



dream.believe.achieve

moving from strength to strength

2005

- First OSD Facility commences Operations (AF)

2008

- Hormonal Production Facility commenced (AF)

2012

- New Sterile FDF Facility commenced (IM)

2014

- New OSD Facility commenced (AG)

2015

- WHO Geneva Pre Qualification/ INVIMA approval (AF)

2016

- UKMHRA / ANVISA / PICS approval (IM)
- EU-GMP approval (AG)
- New R&D Centre at Bangalore commenced operations

Acme Formulation : (AF)

Acme Generics : (AG)

Immacule Lifesciences : (IM)

2017

- TGA, Health Canada (AG)

2019

- USFDA Approval with Zero 483 (IM)
- ANDA Approvals~02
- ANDA Filings~05

2022

- USFDA GMP Inspection Renewal (IM)
- EU GMP renewal* (AF/AG/IM)
- ANDA Approvals~10
- ANDA Filings~15

2023

- Sterile Capacity expansion with investment of USD 50 million
- ONCO/PFS/CARTRIDGE capabilities
- ANDA Filing Target ~50+ (AF/AG/IM)

2025

- USD 200 million revenues
- ANDA Filing target~100+ (AF/AG/IM)





Acme Formulation
Quality Delivered



Acme Formulation

Acme Formulation

Oral solid dosage facility

General and hormonal category

Available dosage

Tablets and capsules

Facility area

100,000 sq. ft.

Capacity

250 million tablets from female sex hormonal block

3 billion tablets, and 1 billion capsules from general block

Approvals

EU-GMP (Hormone Block), WHO-Geneva, Colombia INVIMA, Tanzania, Nigeria, Ethiopia, Ghana, Kenya, Yemen, Zimbabwe, Vietnam, Philippines, Zambia, Mozambique, Niger, Senegal, Sierra Leone, Peru, Chile, Ukraine





Acme Generics

Oral solid dosage facility

General tablets and capsules/
Levothyroxine tablets

Available dosage

Tablets and capsules

Facility area

300,000 sq. ft.

Capacity

6 billion tablets from levothyroxine block per annum
7 billion tablets and 2 billion capsules from general block per annum

Approvals

EU GMP, Health Canada, TGA Australia, MOH Russia, Kazakh, NDA Uganda
2 ANDA Filed in the US shall trigger USFDA inspection for the site in 2022-23

Research & Development

We have an in-house Research and Development wing with 50+ professionals. and capabilities to develop complex generics and potent products

- Generic drug development (US, EU and other emerging markets)
- Innovative Generics (505 B2)
- Dedicated Oncology / High Potency Products Area with Isolators.





Immacule Lifesciences

Sterile Product Facility

Liquid injection and lyophilized vials

Facility

USFDA approved sophisticated state-of-the-art 21 CFR compliant, built with USD 50 million investment.

Available dosage

Aseptic/Terminally Sterilized Vials (1ml-100 ml)/Ampoules (1ml-10 ml)

Capacity

15 million lyophilised vials &

60 million liquid ampoules/vials

10 + ANDA approved, 15 + ANDA under review, 50 + ANDA filing target by 2023.

Upcoming Expansion (Targeted Completion Date Dec: 23)

PFS/Cartridges/liquid & lyophilized injection (vials) in General Category

Liquid/Lyophilized injection in Oncology.


Approvals

USFDA, UK MHRA, Hungary OGYEI, Australia TGA, Health Canada, Brazil - ANVISA, WHO Geneva, SAHPRA, Mexico- COFEPRIS

accelerating wellness

R & D and Manufacturing facilities





partnering success : our prestigious clients





giant strides towards a global footprint



■ AFRICA

Ethiopia, Nigeria, Ghana, Tanzania, Kenya, Uganda, Zambia, Malawi, Sierra Leone, Madagascar, Angola, Zimbabwe, Mozambique, Cameroon, Senegal, South Sudan, South Africa, Ivory Coast

■ ANZ

Australia

■ ASIA

Nepal, Sri Lanka, Philippines, Vietnam, Cambodia, Laos, Thailand, Myanmar, Malaysia, Singapore

■ CENTRAL & SOUTH AMERICA

Brazil, Colombia, Guatemala, Nicaragua, Paraguay, Uruguay, Chile, Costa Rica, Venezuela, Peru, Ecuador, Mexico

■ CIS & OTHERS

Kazakhstan, Uzbekistan, Ukraine, Russia, Georgia

■ EUROPE

United Kingdom, Hungary, Poland, Italy, Netherlands, Portugal, Austria, Czech Republic, Denmark, Germany
































■ MIDDLE EAST

UAE, Saudi Arabia, Yemen

■ NORTH AMERICA

US, Canada

accreditations

 U.S.	 UK	 HUNGARY	 AUSTRALIA	 CANADA	 BRAZIL	 WHO
 UKRAINE	 COLOMBIA	 ZIMBABWE	 FMHACA ETHIOPIA	 TANZANIA	 UGANDA	 GHANA
 PHILIPPINES	 THAILAND	 IVORY COAST	 KENYA	 COMBODIA	 PERU	 SUDAN
 IRAQ	 KAZAKHSTAN	 MALAYSIA	 MEXICO	 RUSSIA	 SAUDI ARABIA	 SOUTH AFRICA
 GUINEA	 MALAWI	 NIGERIA	 YEMEN	 CHILE	 VIETNAM	



Scan here to download
The Corporate Brochure & Product List



Acme Formulation

**Acme
Formulation Pvt. Ltd.**

Ropar Road, Nalagarh,
Distt. Solan, (H.P.) - 174 101
Board Lines : +91 1795-228501-02
Direct Lines : +91 1795-228506
E-mail : viralshah@acmeformulation.com



Acme Generics

**Acme
Generics Pvt. Ltd.**

Plot No.115, HPSIDC Industrial Area,
Davni, P.O. Gurumajra, Tehsil Nalagarh,
Distt. Solan (H.P.) -174 101
Board Lines : +91 1795-248301-02
Direct Lines : +91 1795-248306
E-mail : viral@acmegenerics.com



Immaculé

**Immacule
Lifesciences Pvt. Ltd. India**

Village Thanthewal, Ropar Road,
Nalagarh, Distt. Solan, (H.P.)-174 101
Board Lines : +91 1795-228601-02
Direct Lines : +91 1795-228606
E-mail : viral@immacule.in
www.immacule.in